Review

Bench-to-bedside review: Pulmonary–renal syndromes – an update for the intensivist

Spyros A Papiris¹ , Effrosyni D Manali¹ , Ioannis Kalomenidis¹ , Giorgios E Kapotsis¹ , Anna Karakatsani¹ and Charis Roussos²

¹  2nd Pulmonary Department, National and Kapodistrian University of Athens, 'Attikon' University Hospital, Athens, Greece

²  Department of Critical Care and Pulmonary Services, National and Kapodistrian University of Athens, 'Evangelismos' Hospital, Athens, Greece

author email corresponding author email

Critical Care 2007, 11:213doi:10.1186/cc5778

Published:	2 May 2007

Abstract

The term Pulmonary–renal syndrome refers to the combination of diffuse alveolar haemorrhage and rapidly progressive glomerulonephritis. A variety of mechanisms such as those involving antiglomerular basement membrane antibodies, antineutrophil cytoplasm antibodies or immunocomplexes and thrombotic microangiopathy are implicated in the pathogenesis of this syndrome. The underlying pulmonary pathology is small-vessel vasculitis involving arterioles, venules and, frequently, alveolar capillaries. The underlying renal pathology is a form of focal proliferative glomerulonephritis. Immunofluorescence helps to distinguish between antiglomerular basement membrane disease (linear deposition of IgG), lupus and postinfectious glomerulonephritis (granular deposition of immunoglobulin and complement) and necrotizing vasculitis (pauci-immune glomerulonephritis). Patients may present with severe respiratory and/or renal failure and require admission to the intensive care unit. Since the syndrome is characterized by a fulminant course if left untreated, early diagnosis, exclusion of infection, close monitoring of the patient and timely initiation of treatment are crucial for the patient's outcome. Treatment consists of corticosteroids in high doses, and cytotoxic agents coupled with plasma exchange in certain cases. Renal transplantation is the only alternative in end-stage renal disease. Newer immunomodulatory agents such as those causing TNF blockade, B-cell depletion and mycophenolate mofetil could be used in patients with refractory disease.